UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000002407 |
|---|---|
| Receipt number | R000002944 |
| Scientific Title | Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapy |
| Date of disclosure of the study information | 2009/09/01 |
| Last modified on | 2013/06/27 15:21:55 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapy
Acronym
Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapy
Scientific Title
Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapy
Scientific Title:Acronym
Phase II study of Bevacizumab in combination with FOLFIRI as second-line therapy for patients with metastatic colorectal cancer who have progressed on Bevacizumab with Oxaliplatin-based chemotherapy
Region
| Japan |
Condition
Condition
metastatic colorectal cancer
Classification by specialty
| Gastroenterology | Hematology and clinical oncology | Gastrointestinal surgery |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
To assess the efficacy and safety of Bevacizumab(10mg/kg) in combination with FOLFIRI as second-line therapy after progression on Bevacizumab with Oxaliplatin-based chemotherapy
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Phase II
Assessment
Primary outcomes
Progression free survival
Key secondary outcomes
Safety,Overall response rate,Overall survival,Overall survival from 1st line
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Bevacizumab(10mg/kg) plus FOLFIRI
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1.Histological confirmation of colorectal cancer
2.Measurable lesion
3.documented disease progression(PD) during Bevacizumab with Oxaliplatin-based chemotherapy* or within four weeks thereafter via radiographic assessment *receipt of this regimen for at least two months
4.Age : > 20 years
5.ECOG-PS : 0-2
6.Adequate organ function before fourteen days,defined as leukocyte count >= 3000/mm3(neutrophil cell count >=1500/mm3),platelet count >= 100000/mm3,hemoglobin >=9.0g/dl,Total bilirubin <= 1.5xULN,AST/ALT/ALP <= 2.5xULN,serum creatinine <= 1.5xULN
7.Survival period more than 3 months
8.Written informed consents
Key exclusion criteria
1.clinical or radiological evidence of CNS metastases.
2.current or previous (within the last 1 year) history of cerebrovascular disease
3.major surgical procedure, open biopsy or significant traumatic injury except for CV-port procedure within 28 days prior to Day 0
4.serious non-healing fracture
5.current or previous (within the last 1 year) history of GI perforation
6.serious non-healing ulcer
7.evidence of bleeding diathesis or coagulopathy.
8.current or recent (within 10 days prior to enrllment) ongoing treatment with anticoagulants for therapeutic purposes
9.ongoing treatment with aspirin (> 325 mg/day)
10.clinically significant (i.e. active) cardiovascular disease, or past or current history (within the last 1 year) of myocardial infarction
11.uncontrolled hypertension
12. serious renal failure, 1+ or higher proteinuria within 2 weeks prior to enrollment
13.uncontrolled pleural and/or peritoneal effusion
14.past or current history (within the last 5 years) of malignancies except for the indication under this study and curatively treated:
- Basal and squamous cell carcinoma of the skin
- In-situ carcinoma of the cervix
15.interstitial lung disease, or pulmonary fibrosis
16.uncontrolled infection
17.history of organ transplantation
18.diarrhea >= Grade 2 according to the Common Toxicity Criteria of the National Cancer Institute, version 3.
19.pregnancy (positive serum pregnancy test) and lactation
20.serious drug hypersensitivity or a history of drug allergy
21.history of adverse events related to fluorouracil
22.Any other serious or uncontrolled illness which, in the opinion of the investigator, makes it undesirable for the patient to enter the trial
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | michio nakamura |
Organization
Sapporo City General Hospital
Division name
Divison of Gastrointestinal Oncology and Endoscopy
Zip code
Address
KITA-11 NISHI-13-1-1,CHUO-KU,SAPPORO,060-8604,Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | michio nakamura |
Organization
Sapporo City General Hospital
Division name
Divison of Gastrointestinal Oncology and Endoscopy
Zip code
Address
KITA-11 NISHI-13-1-1,CHUO-KU,SAPPORO,060-8604,Japan
TEL
Homepage URL
Sponsor or person
Institute
Sapporo City General Hospital
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
市立札幌病院（北海道）
Other administrative information
Date of disclosure of the study information
| 2009 | Year | 09 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2009 | Year | 06 | Month | 16 | Day |
Date of IRB
Anticipated trial start date
| 2009 | Year | 08 | Month | 01 | Day |
Last follow-up date
| 2013 | Year | 07 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2009 | Year | 08 | Month | 31 | Day |
Last modified on
| 2013 | Year | 06 | Month | 27 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002944
